On Monday, Christopher & Banks Corporation (NYSE:CBK)’s shares declined -1.07% to $1.38.
Christopher & Banks Corporation (CBK), a specialty women’s apparel retailer, recently stated results for the thirteen week period ended August 1, 2015.
Results for the Thirteen Week Period Ended August 1, 2015
- Net sales totaled $94.0 million, as contrast to $106.6 million for the thirteen weeks ended August 2, 2014. During the quarter, the Company operated an average of 4.4% fewer stores than during the comparable period last year, reflecting its MPW store conversion strategy; offset to some extent by new store openings, primarily outlets.
- Same-store sales reduced 12.4% in the thirteen weeks ended August 1, 2015, as contrast to the thirteen weeks ended August 2, 2014; this follows a 4.7% same-store sales enhance in last year’s second quarter.
- Gross margin was 32.9% contrast to 35.3% in the second quarter of fiscal 2014.
- Operating loss was $1.7 million for the thirteen week period ended August 1, 2015. This compares to operating income of $3.3 million in the second quarter of fiscal 2014.
- Net loss totaled $0.7 million, or ($0.02) per share. Net income for the thirteen weeks ended August 2, 2014 totaled $3.4 million, or $0.09 per diluted share.
Christopher & Banks Corporation, through its auxiliaries, operates as a retailer of women’s apparel and accessories in the United States. The company designs, sources, and sells women’s apparel and accessories to customers ranging in age from 45 to 60. Its stores offer women’s apparel comprising of knit tops, woven tops, jackets, sweaters, skirts, denim bottoms, bottoms made of other fabrics, leisure wear, and dresses in missy, petite, and women sizes, in addition to jewelry and accessories.
Aquinox Pharmaceuticals Inc (NASDAQ:AQXP)’s shares dropped -3.99% to $18.04.
Aquinox Pharmaceuticals, Inc. (AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, declared that it will host an R&D Day in New York City on Wednesday, October 7th from 8:30 AM to 10:00 AM Eastern Time. This event will provide an opportunity to hear from a distinguished clinical expert on bladder pain syndrome/interstitial cystitis (BPS/IC), a debilitating disease affecting millions in the U.S. Aquinox will also be reviewing the full data from its recently accomplished LEADERSHIP trial and provide an update on the clinical development plans for AQX-1125 in BPS/IC.
Senior members of Aquinox’s executive team will be in attendance, counting David Main, President & CEO and Dr. Stephen Shrewsbury, Senior VP of Clinical Development and Chief Medical Officer. Also attending will be Dr. Robert Evans M.D., Associate Professor of Urology at Wake Forest Baptist Health University and Clinical Instructor, Wake Forest School of Medicine Department of Urology. Dr. Evans has been a practicing urologist for more than 25 years while serving on the American Urologic Association guidelines committee for interstitial cystitis in addition to the Medical Advisory Board and the Board of Trustees of the Interstitial Cystitis Association. Dr. Evans is recognized as a foremost authority in the understanding, diagnosis and treatment of BPS/IC.
Aquinox Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in discovering and developing targeted therapeutics for diseases in the areas of inflammation and immuno-oncology.
At the end of Monday’s trade, Ingredion Inc (NYSE:INGR)‘s shares surged 2.33% to $88.67.
The Board of Directors of Ingredion Incorporated (INGR) declared a quarterly dividend of $0.45 per share on the Company`s common stock. The dividend, up from $0.42 per share last quarter, is payable on October 26, 2015, to stockholders of record at the close of business on September 30, 2015.
Ingredion Incorporated, together with its auxiliaries, manufactures and sells starches and sweeteners to various industries. It offers sweetener products comprising glucose syrups, high maltose syrups, high fructose corn syrups, caramel colors, dextrose, polyols, maltodextrins and glucose, and syrup solids, in addition to food-grade and industrial starches.
Hormel Foods Corp (NYSE:HRL), ended its Monday’s trading session with 0.23% gain, and closed at $61.22.
During the annual Barclays Back-to-School Consumer Conference in Boston, Mass., Jeffrey M. Ettinger, chairman of the board, president and chief executive officer at Hormel Foods Corporation (HRL), offered insights on the company’s strategies for driving growth counting innovation efforts, expanding business in China and the success of its recent acquisitions. Ettinger also highlighted consumer trends in portable and nutritious foods, multicultural flavors and expansion into global markets.
Glenn R. Leitch, group vice president and president at Jennie-O Turkey Store, joined Ettinger during the presentation to talk about the impact of the recent outbreak of highly pathogenic avian influenza on the industry and how Jennie-O® products are connecting with consumers.
Hormel Foods Corporation produces and markets various meat and food products worldwide. The company operates in five segments: Grocery Products, Refrigerated Foods, Jennie-O Turkey Store, Specialty Foods, and International & Other.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
